Menu

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2018

  1. 26/11/2018
    MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis
  2. 19/11/2018
    MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa
  3. 15/11/2018
    MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210
  4. 05/11/2018
    MorphoSys AG Announces Third Quarter 2018 Results
  5. 01/11/2018
    MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting
  6. 29/10/2018
    MorphoSys to Host Q3 2018 Conference Call on November 6, 2018
  7. 21/10/2018
    MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference
  8. 19/10/2018
    MorphoSys's Licensee Janssen has Reported That New Tremfya(R) (Guselkumab) 3-Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
  9. 25/09/2018
    MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients
  10. 17/09/2018
    MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2017

  1. 13/07/2017
    Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
    No download available

2016

  1. 15/11/2016
    Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
  2. 15/11/2016
    Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares
  3. 01/10/2016
    Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis
  4. 21/04/2016
    Ad hoc: MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab
  5. 04/04/2016
    Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
  6. 24/02/2016
    Ad hoc: MorphoSys Announces Share Buy-Back Program

2015

  1. 07/05/2015
    Ad hoc: MorphoSys Acquires Peptide Therapeutic Company Lanthio Pharma
  2. 08/04/2015
    Ad hoc: MorphoSys to Start Share Buy-Back Program
  3. 26/03/2015
    Ad hoc: MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration and MorphoSys Updates its Financial Guidance for 2015

Pages

Presentations
and conferences

Thursday, February 28, 2019 - 8:30pm
Webcast: 8th Annual Leerink Partners Global Healthcare Conference

Dr. Simon Moroney will present the Company at the 8th Annual Leerink Partners Global Healthcare Conference on Thursday February 28, 2019, 2:30 pm EST (8:30 pm CET, 7:30 pm GMT), in New York, NY, USA.

Go to Webcast

Archive

Date
Title
MP3

2019

  1. 01/21/2019

    Presentation: Kepler Chevreux German Corporate Conference

  2. 01/14/2019

    Presentation: Commerzbank German Investment Seminar 2019

  3. 01/09/2019

    Webcast: JPMorgan Annual Healthcare Conference 2019

2018

  1. 12/06/2018

    Presentation: Berenberg European Conference 2018

  2. 12/05/2018

    Webcast: Investor & Analyst Event

  3. 11/28/2018

    Presentation: Piper Jaffray Annual Healthcare Conference

  4. 11/26/2018

    Presentation: German Eigenkapitalforum

  5. 11/22/2018

    Presentation: Bryan Garnier 6th Annual Healthcare Conference

  6. 11/06/2018

    Conference Call and Webcast: Q3 2018 Financial Results

  7. 10/03/2018

    Webcast: Leerink Partners Roundtable Series: Rare Disease & Oncology

  8. 09/25/2018

    Presentation: Berenberg and Goldman Sachs Seventh German Corporate Conference

  9. 09/24/2018

    Presentation: Baader Investment Conference

  10. 09/07/2018

    Presentation: Goldman Sachs Eighth Annual Biotech Symposium

  11. 08/28/2018

    Presentation: Commerzbank Sector Conference

  12. 08/02/2018

    Conference Call and Webcast: Q2 2018 Financial Results

  13. 06/20/2018

    Webcast: JMP Securities Life Sciences Conference

  14. 06/06/2018

    Presentation: dbAccess Berlin

  15. 05/21/2018

    Presentation: UBS Global Healthcare Conference

  16. 05/03/2018

    Conference Call and Webcast: Q1 2018 Financial Results

  17. 03/13/2018

    Year End 2017 Conference Call and Webcast

Pages

Pictures

Management Board

Dr. Simon E. Moroney

Chief Executive Officer,
MorphoSys AG

Jens Holstein

Chief Financial Officer,
MorphoSys AG

Dr. Malte Peters

Chief Development Officer,
MorphoSys AG

Dr. Markus Enzelberger

Chief Scientific Officer,
MorphoSys AG

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".